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Purified recombinant proteins and peptides, which are
currently under development in various anti-cancer vac-
cination approaches, lack sufficient immunogenicity.
Therefore, potent adjuvants are needed to induce strong
and persistent anti-tumor immunity. However, currently
only few adjuvants are licensed, most of which primarily
enhance antibody, but not T cell responses.
Here, we demonstrate that a novel, well defined, and
thoroughly characterized RNA-based adjuvant mediates
balanced and long-lasting humoral and cellular immune
responses. Our adjuvant significantly enhances anti-tumor
immunity, and even complete tumor rejection can be
achieved as shown for the syngeneic TC-1 tumor model, a
murine model of human HPV-induced cervical cancer.
Our adjuvant acts locally, promoting strong but transient
up-regulation of anti-viral and pro-inflammatory cytokines,
CXCR3-ligands and cytoplasmic RNA sensors at the injec-
tion site, avoiding any systemic cytokine release. These
changes are followed by activation of different subsets of
immune cells in the draining lymph nodes. In repeated
dose toxicity studies carried out in mice and pigs no toxi-
city events were observed demonstrating an excellent pre-
clinical safety profile. A Phase I first in man clinical trial
testing different doses of RNAdjuvant® alone and in com-
bination with reduced doses of the licensed rabies vaccine
Rabipur® is currently ongoing. Healthy volunteers receive
2 intramuscular injections on days 0 and 21 either with
RNAdjuvant® alone or in combination with 1/20 or 1/10
of the licensed Rabipur® dose. In both groups vaccinations
were well tolerated with mild to moderate injection site
reactions and flu-like symptoms as main side effects. Virus
neutralizing antibody titers (VNTs) are measured on days
14 and 28 and a significant increase in median VNTs is
observed after vaccination with 1/10 dose Rabipur® /
RNAdjuvant® compared to 1/10 dose Rabipur® alone. In
summary, our data suggest that RNAdjuvant® represents a
novel, highly efficacious adjuvant candidate that can
enhance cellular and humoral immune responses.
Preliminary results of a first in human trial show a
favorable safety profile and enhancement of immune
responses in combination with a licensed rabies vaccine
indicating an antigen sparing effect.
While the field of cancer vaccination is currently
obstructed by a lack of potent and safe adjuvants,
RNAdjuvant® has the potential to fill this gap and to
improve the efficacy of many cancer vaccines.
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